Heart disease is often linked to high cholesterol, obesity, or lack of exercise. However, there is mounting evidence that suggests that mental health plays a crucial role in cardiovascular well-being. Stress, anxiety, and depression can silently strain the heart, increasing the risk of serious complications.

A recent study, published in Nature Human Behaviour, showed that loneliness has a significant impact on proteins present in a person's blood. For the study, researchers used data from more than 42,000 participants to explore whether the 9.3% who reported social isolation and 6.4% who reported loneliness had different levels of proteins in their blood compared with those who did not. The researchers then studied data that tracked the health of participants over an average 14-year period.

"We found around 90% of these proteins are linked to the risk of mortality," Dr Chun Shen, Fudan University in China, who is also the lead researcher said. "In addition, about 50% of the proteins were linked to cardiovascular disease, type 2 diabetes and stroke," he added.

Dr Shrey Kumar Srivastav, senior consultant at Sharda Hospital, said that subtle symptoms of heart disease, such as fatigue, shortness of breath, swelling in the lower legs, dizziness, and jaw pain, are often overlooked or attributed to stress and ageing. "Women, in particular, may experience atypical signs like extreme fatigue, indigestion, or upper abdominal pain instead of classic chest pain, leading to delayed diagnosis," he added.

Can Mental Health Issues Trigger Heart Diseases?

Chronic stress can trigger harmful cardiovascular effects, including elevated blood pressure, increased heart rate, and inflammation—key contributors to heart disease. Anxiety and depression further impact heart health by disrupting sleep patterns, raising stress hormone levels, and encouraging unhealthy habits like poor diet and inactivity.

Mental health issues like depression and anxiety have a profound impact on the heart. They don’t just affect emotions but can increase inflammation and put extra strain on the cardiovascular system, warns Dr Srivastav.

Certain risk factors, such as obesity and diabetes, disproportionately affect women, making them more vulnerable to heart failure with preserved ejection fraction (HFpEF). However, due to gender-specific symptom variations, heart disease in women often goes undiagnosed for longer.

Obesity is more prevalent in women than men and is a major risk factor for heart failure. Diabetes, too, has a greater impact on women’s heart health, yet diagnosis and treatment delays are common. Addressing this gap requires increasing awareness, training healthcare providers, and promoting early diagnostic tools,” explains Dr Srivastav.

How Can You Protect Your Heart?

A simple yet effective way to support heart health is by committing to a brisk 30-minute walk daily. Walking not only helps regulate blood pressure and manage weight but also improves circulation and reduces stress.

"Regular physical activity, paired with a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins, significantly lowers cardiovascular risks," advises Dr Srivastav.

Heart disease can often go undetected until a major event occurs, making routine screenings essential.

- For women: Begin screenings around age 30 and continue with regular checkups.

- For men: Start screenings at age 35.

Health screenings, including blood pressure checks, cholesterol tests, and electrocardiograms (ECGs), are critical for early detection of silent heart conditions.

The US Food and Drug Administration (FDA) has approved pirtobrutinib as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a known deletion of chromosome 17p.

The approval expands the use of the targeted cancer drug, which was previously approved for certain patients whose CLL or SLL had returned or stopped responding to earlier treatment. It is developed by Eli Lilly and Company and will be sold under the brand name Jaypirca.

More About Pirtobrutinib

CLL is a type of blood cancer in which the bone marrow produces too many abnormal B lymphocytes, a type of white blood cell. These abnormal cells can build up in the blood, bone marrow and lymph nodes.

SLL is closely associated with CLL, but the cancer cells are found mainly in the lymph nodes. CLL can progress slowly in some people, while others may develop more aggressive disease.

Pirtobrutinib is a Bruton tyrosine kinase (BTK) inhibitor, a type of targeted therapy. BTK is a protein that helps B cells receive signals needed for their growth and survival. By blocking BTK, pirtobrutinib interferes with signals that cancerous B cells depend on.

Unlike older covalent BTK inhibitors, pirtobrutinib is a non-covalent, reversible BTK inhibitor, meaning it binds to BTK differently.

A dose of 200 mg once a day is recommended for newly diagnosed patients covered by this approval. It should be taken until the cancer progresses or side effects become severe.

Also read: 2 Indians Charged In US Over Fake Ozempic Scheme: How To Spot Counterfeit GLP-1 Drugs

Findings From Pirtobrutinib's Trial

The FDA based its decision on the BRUIN CLL-313 trial, which included 282 adults with previously untreated CLL or SLL without a 17p deletion.

Participants were randomly assigned to receive either pirtobrutinib or the chemotherapy combination bendamustine plus rituximab.

After a median follow-up of 28 months, the median progression-free survival could not yet be calculated for patients receiving pirtobrutinib because enough disease-progressing events had not occurred. In the bendamustine-rituximab group, median progression-free survival was 33.5 months.

The risk of disease progression or death was 80% lower with pirtobrutinib than with bendamustine plus rituximab in the trial, based on the reported hazard ratio of 0.20.

However, overall survival data are still not 100% reliable. There were 13 deaths at the time of the primary analysis - three in the pirtobrutinib group and 10 in the comparison group.

Also read: 21% In 80 Weeks: Lancet Study Finds Lilly’s Retatrutide Delivers One Of The Biggest Weight Losses Ever

Pirtobrutinib's Side Effects

The most common non-laboratory side effects reported with pirtobrutinib included:

• Upper respiratory tract infections
• Rash
• COVID-19

According to the FDA, side effects also include infections, bleeding, reduced blood cell counts, abnormal heart rhythms, other cancers, liver toxicity and harm to an unborn baby. Serious adverse reactions occurred in 28% of patients receiving pirtobrutinib in the trial.

The approval gives eligible people with previously untreated CLL or SLL another targeted treatment option that can be taken as a daily oral medicine.

Jennifer A. Woyach, MD, director of the Division of Hematology at The Ohio State University Comprehensive Cancer Center, said, “This approval is grounded in data from BRUIN CLL-313, which showed a significant delay in disease progression for pirtobrutinib compared to chemoimmunotherapy, along with safety and tolerability consistent with its established profile.”

The FDA's decision applies specifically to adults with previously untreated CLL or SLL without a known 17p deletion. It therefore does not mean that pirtobrutinib is automatically the first treatment for every person newly diagnosed with CLL.

UK hospitals are seeing an increase in COVID-19 activity as the SARS-CoV-2 XFG variant, dubbed “American Covid” or “Stratus,” circulates in the country.

According to the latest data from the UK Health Security Agency (UKHSA), COVID positivity in hospital settings increased from 5.9% to 7.0%. The weekly hospital admission rate also rose from 0.81 to 1.20 per 100,000, an increase of about 48%.

London recorded the highest increase among regions, with its COVID hospital admission rate rising by 79%.

More than half of the sequenced positive samples were reported to be XFG. Among people aged over 85, hospital admission rates increased from 7.08 to 12.43 per 100,000.

However, the true number of infections could be higher because fewer people are testing for COVID-19 than during the pandemic.

Also read: Flu 2026: Symptoms To Watch For As New Season Begins

What Is the XFG Variant?

XFG is a recombinant SARS-CoV-2 variant formed from Omicron subvariants LF.7 and LP.8.1.2. The WHO records the earliest documented XFG sample on January 27, 2025, and designated it a variant under monitoring in June 2025.

The variant has since been detected in multiple countries and remains among the SARS-CoV-2 variants being monitored by WHO.

What Are the Symptoms of XFG?

COVID symptoms can vary between individuals. Reported symptoms associated with the current circulation of XFG include:

• Cough

• Fever

• Sore throat

• Headache

• Runny nose

• Fatigue

Some people may also experience muscle and joint aches, gastrointestinal symptoms as well as eye or chest infections, while others may have no symptoms.

London GP Dr Renée Hoenderkamp has highlighted symptoms including sore throat, headache, runny nose, fatigue and flu-like aches, Daily Mail reported.

Read More: WHO Sets 2027 Flu Vaccine Strains; US States Can Now Order Free COVID Shots For Kids

Does XFG Cause More Severe Disease?

There is currently no evidence that the variants circulating in the UK are causing more severe disease.

“There is no evidence that variants currently circulating in the UK are causing more severe disease,” Dr Siggins said. “However, COVID can still cause serious illness in those at greatest risk.”

The latest available figures cited in reports recorded seven deaths involving COVID in England in the week ending August 28, compared with six the previous week.

Older adults and people with underlying conditions remain more vulnerable to severe COVID.

How Worried Should We Be?

The current increase is not comparable with the waves seen during the height of the COVID pandemic. UKHSA classifies the current hospital admission rate as being at a baseline level.

“COVID is increasing, but from a low level, which is not unexpected at this time of year,” said Dr Matthew Siggins, lecturer in immunity and infection biology at the University of Surrey, according to reports.

WHO has assessed the additional public health risk posed by XFG as low at the global level. Current evidence does not indicate that XFG causes more severe illness or deaths than other circulating variants.

How Can You Protect Yourself?

People who develop a high temperature or feel particularly unwell should stay home and avoid contact with others while they recover.

People eligible for the autumn COVID vaccination are advised to get vaccinated to maintain protection against serious illness.

Most people have some immunity from previous infection, vaccination or both. However, immunity may decline over time and does not always prevent infection. Protection against severe disease is generally stronger.

WHO has said currently approved COVID vaccines are expected to continue providing protection against symptomatic and severe disease from XFG.

Robotic technology is set to become an accelerating tool across every specialty of medicine, covering diagnostics, treatment and therapy in India, Union Minister of State (Independent Charge) for Science & Technology Dr. Jitendra Singh said.

Speaking at the inaugural session of the International Conference of the Society of Robotic Surgery in New Delhi, Singh said robotics should not be viewed as technology limited to surgery but as a tool that could increasingly be used across different branches of medicine.

“It’s a tool. It will happen everywhere,” he said, adding that the future could see the emergence of robotic medicine, robotic endocrinology and robotic cardiology, just as AI is finding applications across medical specialties.

Robotics, AI and Precision Medicine

Singh said robotics, artificial intelligence (AI) and nanoscience could create a larger ecosystem for precision health delivery and precision medicine.

Emerging technologies, he said, could enable increasingly personalized healthcare based on an individual's genetic profile, environmental conditions, lifestyle and dietary patterns.

He said the next phase of medicine could see greater use of genetically driven diagnostics alongside advances in quantum technologies, nanomedicine, AI and robotics.

Gene Sequencing for Every Newborn

Singh also expressed a desire to launch gene sequencing for every newborn. Referring to the Genome India Program, he said 10,000 individuals have already been sequenced and that AI and robotics could support detailed genetic sequencing across India's population of 1.4 billion.

He also highlighted the potential of tele-robotics, sharing his experience of performing an ultrasound on a person located 10,000 kilometers away in Antarctica.

How Robotics Is Changing Surgery

The shift toward robotic medicine is already visible in surgery. AIIMS experts recently explained how robotic technology is changing gallbladder surgery, building on the transition from open surgery to laparoscopy and now robotic-assisted procedures.

Professor Hemanga K Bhattacharjee, Department of Surgical Disciplines, AIIMS New Delhi, said inflammation, adhesions, scarring and unexpected anatomy can make gallbladder surgery difficult.

“What the surgeon encounters once the procedure begins can be very different from what was expected. In such situations, robotic-assisted surgery can be an ideal option, as the enhanced visualization and instrument control can help the surgeon navigate difficult anatomy with greater precision,” Bhattacharjee said.

The AIIMS Department of Surgical Disciplines uses the da Vinci robotic system, which provides a high-definition 3D view and wristed instruments for controlled movements. The department has performed more than 1,500 robot-assisted surgeries across specialties, according to hospital authorities.

Will Robotics Replace Laparoscopy?

Dr. Sunil Chumber, Head of the Department of Surgical Disciplines at AIIMS, Delhi, has worked through the evolution from open surgery and mini-laparotomy to laparoscopy and robotic-assisted surgery.

He described robotic-assisted surgery as “a significant step forward” and said he considers it “a superior surgical platform” based on his experience.

“My expectation is that, eventually, gallbladder surgery will be performed robotically and conventional laparoscopy will be phased out,” Chumber said.

“Every generation of surgery builds on what came before it. Laparoscopy was a major advancement in its time, but having worked with robotic-assisted surgery, I believe robotics is the next step in that evolution.”